Pediatrix Medical Group earnings snapshot

Pediatrix Medical Group (MD) has reported its latest quarterly results with Q4 2025 revenue of US$493.8 million, basic EPS of US$0.40 and net income, excluding extra items, of US$33.7 million. The company has seen revenue move from US$502.4 million in Q4 2024 to US$493.8 million in Q4 2025, while basic EPS shifted from US$0.36 to US$0.40 over the same period, giving a view of how the top line and EPS have been tracking into the new year. With trailing twelve month EPS at US$1.97 and net income of US$165.4 million, investors may now focus on how these margins compare with the broader story around Pediatrix’s profitability.

See our full analysis for Pediatrix Medical Group.

With the headline numbers reported, the next step is to see how these results line up with the main narratives around Pediatrix Medical Group, highlighting where the data supports the story and where it offers a different perspective.

Profitability turns around on a trailing basis

• On a trailing twelve month basis, Pediatrix moved from a net loss of US$253.8 million and basic EPS of US$3.06 in Q3 2024 to net income of US$165.4 million and basic EPS of US$1.97 by Q4 2025, alongside revenue of US$1.9b.
• What stands out for the bullish view is that this return to profitability lines up with the description of “high quality earnings,” yet forecast earnings growth is only 0.3% per year, which is slower than the US market at 16%, so
  • Supportive data for bulls includes four straight quarters of positive quarterly net income in 2025, from US$20.7 million in Q1 to US$71.7 million in Q3 and US$33.7 million in Q4.
  • At the same time, the modest 4% revenue growth forecast versus 11.2% for the US market challenges the idea of a strong growth runway, even with the improved profitability.

Some investors see this shift to positive trailing earnings as the start of a longer term turnaround story that could reshape expectations for Pediatrix Medical Group, and they spell out their full case in the 🐂 Pediatrix Medical Group Bull Case

Low P/E and large DCF gap

• The stock trades on a trailing P/E of 10.2x at a share price of US$20.83, compared with a US Healthcare industry average of 24.9x and peer average of 25.1x, while the provided DCF fair value of US$61.38 sits very far above the current price.
• Consensus narrative points to this valuation gap as a potential reward, but also flags slower growth, so
  • The roughly 66.1% discount to the DCF fair value suggests investors are applying a big margin for risk or growth concerns despite the company being profitable over the last year.
  • With revenue expected to grow around 4% per year and earnings growth forecast at 0.3% per year, the low P/E multiple may reflect the market’s focus on these modest growth rates versus the higher US market benchmarks.

Slower growth worries bears

• Revenue is forecast to grow about 4% per year and earnings about 0.3% per year, both below US market forecasts of 11.2% for revenue and 16% for earnings, after a five year period where earnings changed by 15.7% per year.
• Bears argue that slower top line and earnings growth could limit upside even after the move back to profitability, yet the recent numbers give a mixed picture, so
  • The 2025 quarterly revenue range of US$458.4 million to US$493.8 million shows relatively tight movement, which may look steady but does not point to rapid expansion that would quickly close the valuation gap.
  • However, trailing net income of US$165.4 million contrasts with the earlier trailing loss of US$253.8 million in Q3 2024, which challenges the idea that the business cannot sustain profitability if current conditions hold.

Cautious investors focus on these slower growth forecasts and past earnings volatility to argue the stock deserves its current discount, and they outline that case in the 🐻 Pediatrix Medical Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Pediatrix Medical Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of improving profitability and slower growth forecasts feels balanced on both sides, now is a good time to review the data yourself and decide where you stand. To see what optimistic investors are focusing on, start with the 3 key rewards.

Explore Alternatives

Pediatrix Medical Group’s forecasts for roughly 4% revenue growth and 0.3% earnings growth, both below wider US market expectations, highlight a concern around slower expansion.

If that sluggish outlook feels limiting, you can quickly compare this profile with companies screened for stronger potential in the 51 high quality undervalued stocks and see if any better fit your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.